ReachRxResearch
Home
Research
Sign Up
TCR origin and specificity to environmental or self-antigens on distinct antigen-presenting cells determine peripheral Treg cell differentiation
Back to Research Hub
  1. Home
  2. Research Hub
  3. TCR origin and specificity to environmen…

TCR origin and specificity to environmental or self-antigens on distinct antigen-presenting cells determine peripheral Treg cell differentiation

Immunity·July 28Open Access
ImmunologyPractice changingAutoimmunityFood AllergyImmunological ToleranceExperimental/Mechanistic StudyCRISPR-Based TCR EditingRegulatory T Cell TherapyMixed

Summary

View source

What was studied

This study examined how TCR origin and antigen specificity (self, microbial, or dietary) shape peripheral regulatory T (pTreg) cell differentiation, using CRISPR-based TCR editing of primary T cells with a large TCR panel across distinct antigen-presenting cell (APC) contexts.

Key findings

All antigen classes (self, microbial, dietary) drove stable pTreg cell differentiation; TCRs from Treg cells were more effective than those from conventional T cells. Antigen class determined distinct phenotypes—self-reactive TCRs induced Helios⁺ pTregs via conventional dendritic cells, food-reactive TCRs induced RORγ⁺ pTregs via RORγ⁺ APCs, and some TCRs produced dual Helios⁺RORγ⁺ cells—each with distinct transcriptional programs.

Study limitations

The study relies on CRISPR-edited primary T cells with a curated TCR panel, which may not fully reflect the natural diversity of the TCR repertoire in vivo. The generalizability of findings to human immunology is not directly established, as the work appears primarily mechanistic/murine.

Clinical implications

TCR specificity and APC context jointly govern pTreg phenotype, suggesting that TCR selection and antigen-presenting cell targeting are both critical variables when designing TCR-based tolerogenic immunotherapies for food allergy, autoimmunity, or microbiome-related tolerance.

Caveats

  • No sample size (n) is reported in the abstract; sample_size tag omitted.
  • Study design is ambiguous between basic/translational research; labeled as 'Experimental/Mechanistic Study' rather than a standard clinical trial design.
  • The paper is published July 28, 2026; findings are mechanistic and likely murine—species and direct clinical applicability are not explicitly stated in the abstract. The 'practice_changing' flag is applied based on the conceptual framework offered for TCR-based tolerogenic therapy design, but clinical translation has not yet been demonstrated.

Related Questions

Explore related topics

How does TCR specificity influence regulatory T cell phenotype in tolerogenic immunotherapy?What role do antigen-presenting cells play in peripheral Treg cell differentiation for food allergy treatment?Can CRISPR-based TCR engineering be used to design antigen-specific Treg therapies for autoimmune disease?

Publication Details

Year
2026
Journal
Immunity
Source
View article
Keep scrolling
More content below.
Up Next